Ranilair D Tablet contains Domperidone 10mg and Ranitidine 150mg, a combination therapy used to manage gastroesophageal reflux disease (GERD), acid reflux, heartburn, nausea, vomiting, and related gastrointestinal discomfort.
Domperidone enhances gastric motility and reduces nausea, while Ranitidine suppresses stomach acid production, providing comprehensive relief from digestive disorders.
This combination belongs to the gastroenterology and acid-reducing therapy segment, commonly prescribed by gastroenterologists, surgeons, and general physicians.
For PCD pharma franchise partners, distributors, and exporters, Ranilair D Tablet offers a profitable business opportunity due to high demand in GERD and digestive disorder management. It is available for bulk supply, monopoly-based PCD franchise, third-party manufacturing, institutional distribution, and export.